Table 2:
Treatment outcomes for all patients involved in the study.
| Patient | Cycles | IV Chemotherapy | Toxicity | IP tolerance | Results | Survival April 2016 | Overall survival,a months | Global OS,b months |
|---|---|---|---|---|---|---|---|---|
| 1 | 4 | LV5FU2-VECTIBIX | Grade 2 abdominal pain; Grade 2 neutropenia; Grade 3 stomatitis (5FU dose reduction) | Good | Stability | Yes | 12 | 23 |
| 2 | 4 | FOLFIRI AVASTIN | Grade 2 abdominal pain | Very good | Progression | Yes | 14 | 32 |
| 3 | 1 | FOLFIRI AVASTIN | Grade 3 abdominal pain | Good | Complication IP catheter (diffusion)/Progression | No | 7 | 34 |
| 4 | 1 | LV5FU2 | Grade 3 asthenia, Grade 2 vomiting | Good | Palliative care after 1 cycle | No | 3 | 32 |
| 5 | 1 | FOLFIRI-VECTIBIX | Grade 3 diarrhea, severe hypokalemia | Decreased | Progression | Yes | 10 | 17 |
| 6 | 0 | FOLFIRI | – | – | Complication IP catheter perfusion/entero-cutaneous fistula | Yes | 11 | 55 |
IV, intravenous; IP, intraperitoneal; Survival was checked in April 2016 (yes: alive; no: deceased).
a
Overall survival (OS) was calculated from the insertion of the catheter considering deaths from any cause.
b
Global OS was calculated from diagnosis considering deaths from any cause.